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Welcome to the new technology column titled Innovations in Eye Care. The purpose of this column is to educate our 
profession on the latest and future innovations that could impact 
our practices and our patients. It is said that approximately 60–
70% of all patients research medical conditions on the internet 
before seeing their doctors. Sometimes an internet search could 
take them in rather unique and interesting directions related to 
the ocular disease they may have. They will often ask their eye 
doctors about these technologies and if you can answer their 
questions on innovative or future technologies, you will likely 
remain their doctor long-term, since this should instill further 
confidence in you.
Let’s begin with a technology that may have the greatest 
impact on our patients vision and could treat a number of 
blinding conditions.  
Stem Cell Research
By definition a stem cell is an undifferentiated cell of a 
multicellular organism that is capable of giving rise to 
infinitely more cells of the same type, and from which certain 
other kinds of cell arise by differentiation.  Researchers first 
discovered ways to derive stem cells from mice embryos in 
1981. When it comes to the eye, limbal stem cells have long 
been known to be the precursor to epithelial cell growth. The 
ability to harvest these cells in non-controversial ways such as 
from a cadaver eye (allograft) or pluripotent skin stem cells or 
from the patients other eye (autograft) are all being studied or 
currently being applied. 
For example damage to corneal epithelial stem cells 
from trauma including chemical burns or contact lens 
overwear/inappropriate fit has led to epitheliopathies 
and persistent epithelial defects known as limbal stem cell 
deficiency (LSCD). Because the limbal stem cells are critical 
to epithelial healing, traditional corneal transplants typically 
fail. By transplanting the damaged limbal areas first, the 
subsequent corneal transplant is more likely to be successful. 
Limbal stem cell transplantation (from viable existing cells 
otherwise cadaver eyes) has led to recovery of stem cells and 
epithelia healing and recovery in corneas that had previously 
been opacified.1 And the future is even more impressive with 
potential surrounding pluripotent skin stems cells being 
programmed as retinal pigment epithelial (RPE) stem cells for 
the treatment of macular degeneration.2 Pluripotent means 
that the stem cell line can be differentiated into other types of 
cells, not just the type they originated from.  In other words, 
researchers can take skin stem cells and differentiate them 
into multiple lines of RPE cells. Although early in progress, 
the possibilities are life changing. There are companies 
working on stem cell coated contact lenses that may be used 
in patients with a history of aniridia who eventually manifest 
corneal limbal stem cell deficiency, also patients with more 
severe conditions like Steven’s Johnson syndrome, ocular 
pemphigoid, graft versus host disease (GVH) and even post 
chemical eye injuries.
Although there are ethical concerns with other forms of 
stem cells such as embryonic, new research shows that the 
results presented here suggest that human amniotic fluid may 
represent a new source for the isolation of stem cells.1 In fact 
an entire line of RPE stem cells is being cultivated from a 
single source and may be the one source for all patients with 
AMD in the future.  
This knowledge will help patients with longstanding 
opacified corneas where previous transplants have failed, it will 
help patients diagnosed with limbal stem cells issues ranging 
from aniridia and LSCD to the future as a significant treatment 
for patients suffering from age-related macular degeneration.
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